Ajanta Launches Antifungal Drug Voriconazole

Ajanta has launched voriconazole tablets in 50-mg and 200-mg doses in the US market. These tablets are the equivalent generic version of Vfend, an antifungal drug from Pfizer.

Vfend is used to treat conditions such as invasive aspergillosis, candidemia, and serious infections caused by Scedosporium apiospermum and Fusarium species, including Fusarium solani, when other treatments are ineffective.

Pfizer has also launched Vfend on the market in 50-mg and 200-mg doses. However, there is also an injectable version containing 200-mg of voriconazole, as well.

Vfend is not recommended in patients who are pregnant or nursing. It has not been studied in pediatric patients, meaning its safety and efficacy for these individuals remains unestablished. The most common adverse effects associated with Vfend are visual disturbances, fever, nausea, rash, vomiting, chills, and headache. Some patients also experienced tachycardia and hallucinations.

The manner in which the medication is used for treatment depends on the condition of the patient. Those with invasive aspergillosis and serious fungal infections may need to receive Vfend immediately and continue receiving it for 7 days. Individuals with candidemia might need to be treated for a minimum of 14 days. These variations should be considered by patients and their physicians.